文献速递肥胖与代谢综合征糖尿病

胱抑素C是美国代谢综合征成人长期全因死亡与心血管死亡的预测因子

Cystatin C Is a Predictor for Long-Term, All-Cause, and Cardiovascular Mortality in US Adults With Metabolic Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

基于1999-2002年美国国家健康与营养调查前瞻性队列的1980例代谢综合征患者,平均随访15.3±5.4年期间共发生819例死亡。校正变量后,胱抑素C水平与全因死亡、心血管死亡和癌症死亡均相关,且胱抑素C的预测效能优于估算肾小球滤过率、尿素氮、肌酐、尿酸和C反应蛋白。

要点

  • 胱抑素C较高与全因、心血管和癌症死亡率升高相关(P<.05)。
  • 最高三分位组全因死亡HR 1.87、心血管死亡HR 1.97、癌症死亡HR 1.72,均高于最低三分位组。
  • 胱抑素C单独预测全因死亡AUC 0.773、心血管死亡AUC 0.726,联合年龄后分别升至0.861和0.771。

核心结论

  • 胱抑素C水平升高的代谢综合征患者全因死亡、心血管死亡和癌症死亡风险更高。
  • 胱抑素C可能预测代谢综合征患者的全因死亡和心血管死亡。

研究设计与样本

  • 1999-2002年美国国家健康与营养调查(NHANES)前瞻性队列研究,纳入1980例代谢综合征患者。
  • 采用拟合曲线、Kaplan-Meier生存曲线、Cox回归分析和受试者工作特征曲线评估胱抑素C水平与全因、心血管和癌症死亡的关系。

主要发现

  • 平均随访15.3±5.4年期间共发生819例死亡。
  • 拟合曲线和Kaplan-Meier生存曲线显示,胱抑素C水平越高,全因、心血管和癌症死亡率越高(P<.05)。
  • 校正变量后,胱抑素C水平与全因死亡、心血管死亡和癌症死亡的关联分别为1.63(1.42-1.88)、1.53(1.19-1.95)和1.53(1-2.32)(P<.05)。
  • 三分位模型结果一致:与最低三分位组相比,最高三分位组全因死亡HR 1.87(1.43-2.45)、心血管死亡HR 1.97(1.15-3.38)、癌症死亡HR 1.72(1.01-2.91)(P<.05)。
  • 按性别及其他特征进行的亚组研究证实了上述发现;胱抑素C对各类死亡结局的预测效能高于估算肾小球滤过率,并优于尿素氮、肌酐、尿酸和C反应蛋白。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study examined the relationship between cystatin C (CysC) levels and all-cause, cardiovascular disease (CVD), and cancer mortality in US metabolic syndrome (MetS) patients. METHODS: The 1999-2002 National Health and Nutrition Examination Survey (NHANES) prospective cohort research included 1980 MetS participants. To assess CysC levels and all-cause, CVD, and cancer mortality, fitted curves, Kaplan-Meier survival curves, Cox regression analysis, and receiver operating characteristic curves were performed. RESULTS: During a mean follow-up of 15.3 ± 5.4 years, a total of 819 deaths occurred. The fitted and Kaplan-Meier survival curves revealed that greater CysC levels were linked to higher all-cause, CVD, and cancer mortality rates (P < .05). After adjusting for variables, CysC level was associated with all-cause, CVD, and cancer mortality at 1.63 (1.42-1.88), 1.53 (1.19-1.95), and 1.53 (1 ∼ 2.32), respectively (P < .05). Tertile models showed consistent results: high CysC Tertile participants showed higher risk of all-cause mortality (HR 1.87; 1.43-2.45), CVD mortality (HR 1.97, 1.15 ∼ 3.38), and cancer mortality (HR 1.72, 1.01 ∼ 2.91) compared to those in the lowest tertile (P < .05). Subgroup studies by sex and other characteristics confirmed the findings. CysC demonstrated the higher predictive efficacy across mortality outcomes, followed by eGFR, outperforming urea nitrogen, creatinine, uric acid, and C-reactive protein. CysC alone exhibited substantial predictive value for all-cause (AUC 0.773; P < .05) and CVD mortality (AUC 0.726; P < .05). Combining CysC with age enhanced predictive value for all-cause mortality to 0.861 and CVD mortality to 0.771 (P < .05). CONCLUSION: MetS patients with elevated CysC levels have a higher risk of all-cause, CVD, and cancer death. CysC may predict MetS all-cause and CVD mortality.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Song X, Xiong L, Guo T, et al. Cystatin C Is a Predictor for Long-Term, All-Cause, and Cardiovascular Mortality in US Adults With Metabolic Syndrome. J Clin Endocrinol Metab. 2024. PMID: 38597157. doi:10.1210/clinem/dgae225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。